Eli Lilly's Donanemab Receives Approval in India for Alzheimer's Treatment
Deep News
Nov 19
Eli Lilly (India) announced on Tuesday that it has received marketing approval from India's Central Drugs Standard Control Organization for donanemab, a drug used to treat Alzheimer's disease.
The approval specifically covers patients in the early symptomatic stages of Alzheimer's, including those with mild cognitive impairment and mild dementia. Treatment with donanemab requires confirmation of amyloid pathology in patients.
This regulatory approval makes India one of the markets where Eli Lilly can distribute its Alzheimer's treatment drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.